Walleye Capital LLC Sells 234,105 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Walleye Capital LLC cut its holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 94.3% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 14,183 shares of the biopharmaceutical company's stock after selling 234,105 shares during the period. Walleye Capital LLC's holdings in Catalyst Pharmaceuticals were worth $296,000 as of its most recent filing with the SEC.

Other institutional investors have also modified their holdings of the company. Steward Partners Investment Advisory LLC bought a new stake in shares of Catalyst Pharmaceuticals during the fourth quarter valued at approximately $27,000. Farther Finance Advisors LLC raised its stake in Catalyst Pharmaceuticals by 125.1% during the 4th quarter. Farther Finance Advisors LLC now owns 2,690 shares of the biopharmaceutical company's stock valued at $56,000 after acquiring an additional 1,495 shares in the last quarter. Wilmington Savings Fund Society FSB acquired a new position in Catalyst Pharmaceuticals during the 4th quarter worth $65,000. KBC Group NV grew its stake in shares of Catalyst Pharmaceuticals by 48.8% in the fourth quarter. KBC Group NV now owns 4,699 shares of the biopharmaceutical company's stock worth $98,000 after purchasing an additional 1,542 shares in the last quarter. Finally, Thurston Springer Miller Herd & Titak Inc. bought a new position in shares of Catalyst Pharmaceuticals in the fourth quarter worth $134,000. Institutional investors own 79.22% of the company's stock.

Insider Buying and Selling at Catalyst Pharmaceuticals

In related news, insider Brian Elsbernd sold 62,975 shares of the stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $22.98, for a total value of $1,447,165.50. Following the completion of the sale, the insider now directly owns 188,564 shares of the company's stock, valued at approximately $4,333,200.72. This represents a 25.04 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Gary Ingenito sold 44,904 shares of the firm's stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $22.09, for a total value of $991,929.36. Following the sale, the insider now owns 68,873 shares of the company's stock, valued at $1,521,404.57. The trade was a 39.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 10.40% of the company's stock.

Catalyst Pharmaceuticals Stock Up 1.1 %

Shares of NASDAQ CPRX traded up $0.26 during mid-day trading on Friday, hitting $23.45. 612,029 shares of the company traded hands, compared to its average volume of 1,108,879. Catalyst Pharmaceuticals, Inc. has a 1 year low of $14.47 and a 1 year high of $26.16. The stock has a market capitalization of $2.86 billion, a price-to-earnings ratio of 19.87, a PEG ratio of 3.31 and a beta of 0.79. The business has a 50 day moving average of $22.58 and a two-hundred day moving average of $22.22.

Wall Street Analysts Forecast Growth

CPRX has been the subject of several research analyst reports. HC Wainwright reaffirmed a "buy" rating and issued a $35.00 price objective on shares of Catalyst Pharmaceuticals in a report on Friday, February 28th. Robert W. Baird raised their price objective on shares of Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the company an "outperform" rating in a research note on Monday, March 3rd. Baird R W raised Catalyst Pharmaceuticals to a "strong-buy" rating in a report on Monday, February 3rd. Stephens reaffirmed an "overweight" rating and set a $33.00 price target on shares of Catalyst Pharmaceuticals in a research note on Thursday, February 27th. Finally, StockNews.com raised Catalyst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Friday, February 28th. Seven research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Buy" and a consensus target price of $32.29.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.